Two opposite answers to “what are you actually buying?” — a navigator into brand product and coverage, versus a women-positioned storefront for compounded “personalization.”
The two models
Ro plays the insurance-navigation game better than most of the category: coverage checks, prior-authorization support, and — since its 2025 arrangement to dispense Lilly’s Zepbound vials — a direct lane to brand product at manufacturer self-pay prices. Its own fees, effective monthly totals, and compounded posture remain in our verification queue, so no Ro figure appears here yet.
Hers is Hims’ women-focused sibling, sharing the platform, the post-Novo compounded “personalization” posture, and the aggressive entry pricing — wrapped in women’s-health positioning. The same questions apply: maintenance-dose truth, fee stack, and legal lane, all pending verification in our queue.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Brand lane versus wrapper
Ro’s cleanest pitch is procedural — coverage checked, brand vials dispensed at manufacturer pricing when insurance fails. Hers’ pitch is identity — a platform speaking to women’s health, dispensing the compounded product whose legal lane remains contested. A reader choosing between them is really choosing between product certainty and brand affinity; the checklist questions apply identically to both checkouts, and neither’s true totals are verified yet.
Go deeper
Full files: Ro · Hers. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.